Urosepsis: Current therapy and diagnosis;Urosepsis: Aktuelle therapie und diagnostik

Urologe - Ausgabe A

Volumn 44, Issue 4, 2005, Pages 413-424

  Book, M ^a   Lehmann, L E ^a   Schewe, J C ^a   Weber, S ^a   Stuber F ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Sepsis diagnosis; Sepsis therapy; SIRS; Urinary tract infection; Urosepsis

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BLOOD CLOTTING FACTOR 12; CARBAPENEM; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN; CEPHALOSPORINASE; CYTOKINE RECEPTOR ANTAGONIST; GAMMA INTERFERON; GENTAMICIN; INSULIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE; LEVOFLOXACIN; MEROPENEM; OFLOXACIN; OXYGEN; PENICILLIN DERIVATIVE; PROTEIN C; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; TAZOBACTAM; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VASOPRESSIN;

ANTIMICROBIAL THERAPY; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; ECHOGRAPHY; ENTEROBACTER; ESCHERICHIA COLI; GENETIC POLYMORPHISM; HOSPITAL INFECTION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; KLEBSIELLA; LYMPHOCYTE; MEDICAL PRACTICE; MORTALITY; NEUTROPHIL; NONHUMAN; OUTPATIENT; PATHOPHYSIOLOGY; PROTEUS; PSEUDOMONAS AERUGINOSA; REVIEW; SEPSIS; THROMBOCYTE; URINARY TRACT INFECTION; UROSEPSIS;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, URINARY; BACTERIAL INFECTIONS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROGNOSIS; SEPSIS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 18844446662     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-005-0804-x     Document Type: Review

References (18)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310
3. Brun-Buisson C (2000) The epidemiology of the systemic inflammatory response. Intensive Care Med 26 [Suppl1]: S64-S74
4. Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, Sollet JP, Bates BM, Utterback BG, Maki D (2003) The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. Crit Care Med 31:2291-2301
5. Green DR, Beere HM (2000) Apoptosis. Gone but not forgotten. Nature 405:28-29
6. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buchman TG, Karl IE (2001) Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 166:6952-6963
7. Johnson K, Aarden L, Choi Y, De Groot E, Creasey A (1996) The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 87:5051-5060
8. Lederer JA, Rodrick ML, Mannick JA (1999) The effects of injury on the adaptive immune response. Shock 11:153-159
9. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250-1256
10. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N.Engl J Med 348:1546-1554
11. Meakins JL, Pietsch JB, Bubenick O, Kelly R, Rode H, Gordon J, MacLean LD (1977) Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg 186:241-250
12. Oberholzer A, Oberholzer C, Moldawer LL (2001) Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16:83-96
13. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368-1377
14. Santos MC, Woolley DS, Quinn JV, Slotman GJ (1999) Interleukin-1 mediates hemodynamic dysfunction and release of eicosanoids and tumor necrosis factor during graded bacteremia. Shock 11:423-428
15. Schottmüller (1914) Klassische Definition der Sepsis. Verhandl dt Kongress Inn Med 31:257-280
16. Slotman GJ, Friedman B, Brathwaite C, Mure AJ, Quinn JV, Shapiro E (1995) Interleukin-1 mediates increased plasma levels of eicosanoids and cytokines in patients with sepsis syndrome. Shock 4:318-323
17. Van den BG, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P (2003) Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 31:359-366
18. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I (1997) Immunosuppressive effects of apoptotic cells. Nature 390:350-351